India-Japan Pact Targets 5 Sectors to Forge China-Proof Supply Chains

For supply chain professionals, the July 3 declaration is a game-changer. It moves beyond diplomatic broad‑brush statements into tangible commitments to co‑invest in semiconductor fabs, secure rare‑earth processing outside China, and establish joint stockpiles of critical minerals. This provides a concrete roadmap for reducing single‑source dependencies that have long plagued automotive, electronics, and renewable energy supply chains.

India and Japan have taken a decisive step to fortify their economic security partnership, unveiling a Joint Declaration on Economic Security Cooperation on July 3, 2026. The agreement explicitly targets five strategic sectors — semiconductors, critical minerals, information and communication technology (ICT), clean energy, and pharmaceuticals — with the overarching goal of building resilient supply chains and countering economic coercion. Far from being a routine diplomatic communiqué, this declaration represents a concrete attempt to operationalize the two countries' shared vision of strategic autonomy amid rising global trade tensions, particularly with China.

“

India and Japan have taken a decisive step to fortify their economic security partnership, unveiling a Joint Declaration on Economic Security Cooperation on July 3, 2026.

The declaration arrives as supply chain vulnerabilities have become a paramount concern for economic ministers worldwide. Both nations have borne the brunt of pandemic-era semiconductor shortages, rare-earth export controls, and price manipulation in critical industrial inputs. By naming specific sectors, India and Japan are signaling that they will move beyond rhetoric to project-based collaboration and public-private partnerships. This is critical: the declaration is not merely a statement of intent but a framework that mandates “strategic and practical guidance,” implying tangible initiatives, joint investments, and technology transfer mechanisms.

In the semiconductor domain, the pact commits both sides to “strengthen and diversify supply chains in the manufacturing of semiconductors” and to deepen cooperation in manufacturing and research. Japan brings a mature semiconductor equipment and materials industry, while India is investing heavily in fab infrastructure through its Production Linked Incentive (PLI) scheme. Combining Japan's technological edge with India's emerging manufacturing base could partially decouple regional supply chains from Chinese dominance. The agreement could accelerate the establishment of joint R&D centers and cross-border semiconductor clusters, enhancing overall resilience.

Critical minerals have emerged as a choke point in the global energy transition. China controls a majority of rare-earth processing and significant shares of lithium, cobalt, and graphite processing. The declaration explicitly calls out “arbitrary export restrictions” on critical minerals and underpins the need for collective resilience. India and Japan, both heavily dependent on imports of these minerals, are now signaling a joint approach to secure diversified sources, potentially through shared investments in mining projects in third countries such as Australia, Africa, and Latin America. This could include joint stockpiling and recycling initiatives, which are vital for electric vehicle batteries and clean energy technologies.

Clean energy cooperation is another pillar. The declaration emphasizes joint efforts in hydrogen, ammonia, and renewable energy technologies. Japan is a leader in hydrogen fuel cells and carbon capture, while India has massive renewable energy deployment targets and a growing green hydrogen mission. By aligning their initiatives, the two nations can create integrated supply chains for electrolyzers, fuel cells, and energy storage systems. This could reduce costs and accelerate adoption across the Indo-Pacific region, directly challenging China's dominance in solar panel and battery manufacturing.

The pharmaceuticals sector, often overlooked in geopolitical discussions, is integral to this pact. India is the world's largest supplier of generic drugs, and Japan represents a high-value market with stringent quality standards. The COVID-19 pandemic exposed overdependence on active pharmaceutical ingredient (API) imports from China. The declaration enables coordinated strategies to build API and vaccine manufacturing hubs in India that meet Japanese regulatory requirements, while Japan can provide advanced biotech capabilities. This not only secures medicine supply chains but also opens avenues for co-development of novel therapies.